Merck's Q3 earnings highlight strong revenue growth in Oncology and Vaccines, along with an optimistic full-year revenue guidance increase. However, the significant reduction in EPS guidance from approximately $3 to $1.36, primarily due to one-time charges and collaboration costs, may overshadow the positive aspects and lead to short-term investor concerns.

[-1]